Core Scientific (NASDAQ: CORZ) officer sells 10,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Core Scientific, Inc. officer Todd M. Duchene sold 10,000 shares of Common Stock in an open-market transaction at a weighted average price of $16.4865 per share. After this sale, he directly holds 2,037,089 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, and the shares were sold in multiple transactions at prices ranging from $16.285 to $16.78.

Insights

Equity compensation and insider-trading analyst

Routine planned sale of a small portion of holdings.

Todd M. Duchene sold 10,000 shares of Core Scientific Common Stock at a weighted average price of $16.4865 per share in an open-market trade. This was a non-derivative transaction with shares held directly.

The filing shows he continues to hold 2,037,089 shares after the sale, indicating that only a small fraction of his position was sold. A footnote states the transaction was made under a Rule 10b5-1 trading plan adopted on December 5, 2025, suggesting the timing was pre-scheduled rather than reactive to short-term news.

The price range for the individual trades was $16.285 to $16.78, reflecting typical market execution around the weighted average. Overall, this appears to be a routine liquidity event within a trading plan rather than a major shift in insider ownership.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($164,865)

Net Sell 1 txn

Insider DUCHENE TODD M

Role See remarks

Sold 10,000 shs ($165K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$16.4865	$165K

Holdings After Transaction: Common Stock — 2,037,089 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.285 to $16.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Key Figures

Shares sold: 10,000 shares Weighted average sale price: $16.4865 per share Post-transaction holdings: 2,037,089 shares +2 more

5 metrics

Shares sold 10,000 shares Open-market sale on April 6, 2026

Weighted average sale price $16.4865 per share Common Stock sale

Post-transaction holdings 2,037,089 shares Shares directly owned after sale

Trade price range $16.285–$16.78 per share Individual sale transactions

10b5-1 plan adoption date December 5, 2025 Plan governing reported sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.285 to $16.78, inclusive."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DUCHENE TODD M

(Last) (First) (Middle)

C/O CORE SCIENTIFIC, INC.

838 WALKER ROAD, SUITE 21-2105

(Street)

DOVER DELAWARE 19904

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Core Scientific, Inc./tx [ CORZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/06/2026		S(1)		10,000	D	$16.4865(2)	2,037,089	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.285 to $16.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Remarks:

Chief Legal and Administrative Officer

	/s/ Todd DuChene	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CORZ officer Todd M. Duchene report?

Todd M. Duchene reported selling 10,000 shares of Core Scientific Common Stock in an open-market transaction. The weighted average sale price was $16.4865 per share, with trades executed within a defined price range on April 6, 2026.

At what prices did Todd M. Duchene sell CORZ shares?

The reported weighted average sale price was $16.4865 per share. According to the filing, individual trades occurred at prices ranging from $16.285 to $16.78 per share, all executed on the same transaction date.

How many CORZ shares does Todd M. Duchene hold after this sale?

After selling 10,000 shares, Todd M. Duchene directly holds 2,037,089 shares of Core Scientific Common Stock. This indicates he retained a substantial ownership position following the reported open-market transaction.

Was the CORZ insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by Todd M. Duchene on December 5, 2025. Such plans pre-schedule trades, reducing the significance of short-term timing decisions.

What type of transaction code was used in the CORZ Form 4 filing?

The transaction used code “S”, indicating a sale of non-derivative securities. The filing describes it as an open-market sale of Common Stock, with shares directly owned by the reporting person after the transaction.